Cover Image
市場調查報告書

Novo Nordisk A/S的產品平台分析

Novo Nordisk A/S - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224556
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
Novo Nordisk A/S的產品平台分析 Novo Nordisk A/S - Product Pipeline Review - 2016
出版日期: 2016年03月16日 內容資訊: 英文 97 Pages
簡介

Novo Nordisk A/S是全球性的醫藥品企業,從事糖尿病治療產品及生物醫藥品的開發,製造,銷售。

本報告提供Novo Nordisk A/S的治療藥開發平台現況及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Novo Nordisk A/S的基本資料

  • Novo Nordisk A/S概要
  • 主要資訊
  • 企業資料

Novo Nordisk A/S:R&D概要

  • 主要的治療範圍

Novo Nordisk A/S:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Novo Nordisk A/S:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Novo Nordisk A/S:藥物簡介

  • (insulin degludec + insulin aspart)
  • (insulin degludec + liraglutide)
  • insulin degludec
  • liraglutide (recombinant)
  • NN-1218
  • NN-9535
  • nonacog beta pegol
  • somatropin
  • turoctocog alfa pegol
  • NN-8828
  • OG-217SC
  • OI-338GT
  • Oral Insulin
  • concizumab
  • G-530L
  • LAI-287
  • LAI-338
  • NN-1957
  • NNC-01740833
  • OG-987GT
  • OG-987SC
  • semaglutide
  • 第一型糖尿病免疫療法

Novo Nordisk A/S:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Novo Nordisk A/S:最近的開發平台趨勢

Novo Nordisk A/S:暫停中的計劃

Novo Nordisk A/S:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • balaglitazone
    • coagulation factor XIII A-subunit (recombinant)
    • NN-1952
    • NN-1954
    • NN-1955
    • NN-1956
    • NN-1998
    • NN-7128
    • NN-7129
    • NN-8555
    • NN-8828
    • NN-9112
    • NN-9161
    • NN-9925
    • NNC126-0083
    • OG-217GT
    • ragaglitazar
    • tifenazoxide
    • vatreptacog alfa (activated)

Novo Nordisk A/S:企業發表

Novo Nordisk A/S:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07988CDB

Summary

Global Markets Direct's, 'Novo Nordisk A/S - Product Pipeline Review - 2016', provides an overview of the Novo Nordisk A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novo Nordisk A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Novo Nordisk A/S
  • The report provides overview of Novo Nordisk A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Novo Nordisk A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Novo Nordisk A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Novo Nordisk A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Novo Nordisk A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Novo Nordisk A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Novo Nordisk A/S Snapshot
    • Novo Nordisk A/S Overview
    • Key Information
    • Key Facts
  • Novo Nordisk A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Novo Nordisk A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Novo Nordisk A/S - Pipeline Products Glance
    • Novo Nordisk A/S - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Novo Nordisk A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Novo Nordisk A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Novo Nordisk A/S - Drug Profiles
    • (insulin aspart + insulin degludec)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (insulin degludec + liraglutide)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • insulin degludec
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-1218
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nonacog beta pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-9535
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somapacitan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • turoctocog alfa pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • liraglutide (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • liraglutide (recombinant) + NN-8828
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-9536
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-9709
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OG-217SC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OI-338GT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-833
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • concizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-530L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LAI-287
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-1406
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-9747
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NN-9748
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OI-320GT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Insulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Agonize NMUR1 and NMUR2 for Obesity and Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XMet-A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Novo Nordisk A/S - Pipeline Analysis
    • Novo Nordisk A/S - Pipeline Products by Target
    • Novo Nordisk A/S - Pipeline Products by Route of Administration
    • Novo Nordisk A/S - Pipeline Products by Molecule Type
    • Novo Nordisk A/S - Pipeline Products by Mechanism of Action
  • Novo Nordisk A/S - Recent Pipeline Updates
  • Novo Nordisk A/S - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • balaglitazone
      • coagulation factor XIII A-subunit (recombinant)
      • LAI-338
      • liraglutide (recombinant)
      • NN-1952
      • NN-1954
      • NN-1955
      • NN-1956
      • NN-1998
      • NN-7128
      • NN-7129
      • NN-8555
      • NN-8828
      • NN-9112
      • NN-9161
      • NN-9925
      • NNC126-0083
      • OG-217GT
      • OG-987GT
      • OG-987SC
      • ragaglitazar
      • semaglutide
      • tifenazoxide
      • vatreptacog alfa (activated)
  • Novo Nordisk A/S - Company Statement
  • Novo Nordisk A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Novo Nordisk A/S, Key Information
  • Novo Nordisk A/S, Key Facts
  • Novo Nordisk A/S - Pipeline by Indication, 2016
  • Novo Nordisk A/S - Pipeline by Stage of Development, 2016
  • Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016
  • Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016
  • Novo Nordisk A/S - Partnered Products in Pipeline, 2016
  • Novo Nordisk A/S - Partnered Products/ Combination Treatment Modalities, 2016
  • Novo Nordisk A/S - Pre-Registration, 2016
  • Novo Nordisk A/S - Phase III, 2016
  • Novo Nordisk A/S - Phase II, 2016
  • Novo Nordisk A/S - Phase I, 2016
  • Novo Nordisk A/S - Preclinical, 2016
  • Novo Nordisk A/S - Pipeline by Target, 2016
  • Novo Nordisk A/S - Pipeline by Route of Administration, 2016
  • Novo Nordisk A/S - Pipeline by Molecule Type, 2016
  • Novo Nordisk A/S - Pipeline Products by Mechanism of Action, 2016
  • Novo Nordisk A/S - Recent Pipeline Updates, 2016
  • Novo Nordisk A/S - Discontinued Pipeline Products, 2016
  • Novo Nordisk A/S, Subsidiaries

List of Figures

  • Novo Nordisk A/S - Pipeline by Indication, 2016
  • Novo Nordisk A/S - Pipeline by Stage of Development, 2016
  • Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016
  • Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016
  • Novo Nordisk A/S - Partnered Products in Pipeline, 2016
  • Novo Nordisk A/S - Pipeline by Top 10 Target, 2016
  • Novo Nordisk A/S - Pipeline by Route of Administration, 2016
  • Novo Nordisk A/S - Pipeline by Molecule Type, 2016
  • Novo Nordisk A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top